Understanding the molecular mechanisms underlying liver fibrogenesis is fundamentally
relevant to developing new treatments that are independent of the underlying etiology. The
increasing success of antiviral treatments in blocking or reversing the fibrogenic progression
of chronic liver disease has unearthed vital information about the natural history of fibrosis
regression, and has established important principles and targets for antifibrotic drugs.
Although antifibrotic activity has been demonstrated for many compounds in vitro and in …